Doctoral Degree
Ph.D., Biomedical Sciences, Mayo Clinic Graduate School of Biomedical Sciences (2022)
Master's Degree
M.P.H., T.H. Chan School of Public Health, Harvard University (2023)
Research Interests
Genetic Predisposition; Precision Medicine; Cancer Prevention; DNA Damage Signaling; Disease Modeling; Molecular Pharmacology
Primary Preceptor/Branch/Division
Mitchell Machiela, Sc.D., M.P.H. , Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology & Genetics (DCEG)
Publications
Kanakkanthara A, Hou X, Ekstrom TL, Zanfagnin V, Huehls AM, Kelly RL, Ding H, Larson MC, Vasmatzis G, Oberg AL, Kaufmann SH, Mansfield AS, Weroha SJ, Karnitz LM. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Res. 2022 Jan 15;82(2):307-319. doi: 10.1158/0008-5472.CAN-21-0732. Epub 2021 Nov 22. PMID: 34810199.
Kelly RL, Huehls AM, Venkatachalam A, Huntoon CJ, Machida YJ, Karnitz LM. Intra-S phase checkpoint kinase Chk1 dissociates replication proteins Treslin and TopBP1 through multiple mechanisms during replication stress. J Biol Chem. 2022 Apr;298(4):101777. doi: 10.1016/j.jbc.2022.101777. Epub 2022 Feb 26. PMID: 35231445.
Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028. eCollection 2021 Sep. PMID: 34316715.
Kelly RL, Walsh JR, Paratz JD, Yerkovich ST, McKenzie SC, Morris NR. Quadriceps Muscle Strength and Body Mass Index Are Associated With Estimates of Physical Activity Postheart Transplantation. Transplantation. 2019 Jun;103(6):1253-1259. doi: 10.1097/TP.0000000000002488. PMID: 30335695.
Vincelette ND, Ding H, Huehls AM, Flatten KS, Kelly RL, Kohorst MA, Webster J, Hess AD, Pratz KW, Karnitz LM, Kaufmann SH. Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. Sci Rep. 2019 Mar 5;9(1):3617. doi: 10.1038/s41598-019-40218-0. PMID: 30837643.